Publicaciones en colaboración con investigadores/as de Radboud University Nijmegen Medical Centre (8)

2023

  1. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

2020

  1. Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: Laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey

    International Journal of Gynecological Cancer, Vol. 30, Núm. 6, pp. 819-824

  2. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    International Journal of Cancer, Vol. 146, Núm. 2, pp. 439-448

2019

  1. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087

  2. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

    International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1141-1147

2016

  1. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

    Cancer Immunology, Immunotherapy

  2. Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525

  3. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial

    International Journal of Gynecological Cancer, Vol. 26, Núm. 5, pp. 898-905